Almac Pharma Services has successfully supported the packaging and rapid launch of Provention Bio Inc’s product, TZIELD (teplizumab-mzwv) into the U.S. market.   TZIELD was recently approved by the U.S. FDA for intravenous use as the first and only immunomodulatory treatment to delay the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older with stage 2 T1D. Stage 3 T1D is associated with significant health risks, including diabetic ketoacidosis, which can be life threate...